EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo

Lohitesh Kovooru, Jingjing Zhang, Francesco Giuseppe Monni, Tanmoy Dutta, Xiangdong Gongye, Bernice Asiedu, Patrizia Infelise, Emelie Barreby, Oveis Jamialahmadi, Margit Mahlapuu, Rosellina M Mancina, Stefano Romeo

Clinical and Molecular Hepatology · 01.04.2026 · 32 (2) · 829-842

DOI: 10.3350/cmh.2025.1261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.04.2026. Verfasst von Lohitesh Kovooru und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: SciLifeLab, BioMS, Wallenberg Foundation via the Wallenberg Centre for Molecular and Translational Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide and is driven by metabolic reprogramming that supports tumor growth and progression. A common missense genetic variant (rs2642438, p.A165T) in mitochondrial amidoxime reducing component 1 (MTARC1), identified as protective against liver disease, has been recently associated with lower prevalence of steatosis, cirrhosis, and HCC. However, the mechanistic role of MTARC1 in HCC is unclear. Therefore, we sought to decipher the role of MTARC1 in HCC.

Methods

We investigated the role of MTARC1 in HCC by performing siRNA-mediated knockdown across human immortalized HCC cell lines (Hep3B2, HuH7, HepG2 and HepaRG) homozygous for the risk allele (p.A165) and by generating stable CRISPR-Cas9 knockout (KO) models. Next, we assessed the effect of MTARC1 loss on cell proliferation, migration, lipid metabolism, and fatty acid oxidation in vitro, as well as tumor aggressiveness in a subcutaneous xenograft mouse model. Additionally, we performed global proteomics in both in vitro and xenograft models.

Results

Transient knockdown of MTARC1 p.A165 reduced proliferation in HCC cell lines. CRISPR-Cas9-mediated stable MTARC1 p.A165 KO in Hep3B2 cells led to decreased neutral lipid intracellular accumulation, enhanced β-oxidation and reduced cell migration. An MTARC1 KO xenograft model had reduced tumor volume. Proteomic analyses of both in vitro HCC cells and xenograft tumors revealed inhibition of oncogenic pathways and activation of anti-proliferative proteins.

Conclusions

Downregulation of MTARC1 p.A165 inhibits lipid accumulation, dampens tumor-promoting pathways and restricts tumor growth, highlighting MTARC1 as a promising therapeutic target for HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHumansAnimalsCell ProliferationMiceCell MovementCell Line, TumorRNA, Small InterferingLipid MetabolismMice, NudeFatty AcidsCRISPR-Cas Systems

Stichwörter der Autor:innen

EMTFatty acid degradationHypoxiaMTARC1Subcutaneous xenograft model

Substanzen

RNA, Small InterferingFatty Acids

Autor:innen und Institutionen

  • Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
  • Centre for Reproduction, Metabolism and Molecular medicine (CeRM), Department of Medicine (H7), Karolinska Institute, Huddinge, Sweden.
  • Department of Chemistry and Molecular Biology, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.
  • National Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy.
  • Department of Life Science, Health, and Health Professions, Link Campus University, Rome, Italy.
  • Research Unit of Clinical Medicine and Hepatology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.

Förderung

  • SciLifeLab
  • BioMS
  • Wallenberg Foundation via the Wallenberg Centre for Molecular and Translational Medicine
  • Swedish Cancerfonden
  • Swedish Research Council
  • Agreement between the Swedish government and the county councils
  • Swedish Heart Lung Foundation
  • Novonordisk Distinguished Investigator Grant - Endocrinology and Metabolism

Zitieren

APA

Kovooru, L., Zhang, J., Monni, F. G., Dutta, T., Gongye, X., Asiedu, B., Infelise, P., Barreby, E., Jamialahmadi, O., Mahlapuu, M., Mancina, R. M., & Romeo, S. (2026). MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo. Clinical and Molecular Hepatology, 32(2), 829-842. https://doi.org/10.3350/cmh.2025.1261

Vancouver

Kovooru L, Zhang J, Monni FG, Dutta T, Gongye X, Asiedu B, et al. MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo. Clinical and Molecular Hepatology. 2026;32(2):829-842. doi:10.3350/cmh.2025.1261

BibTeX
@article{Kovooru2026,
  author = {Kovooru, Lohitesh and Zhang, Jingjing and Monni, Francesco Giuseppe and Dutta, Tanmoy and Gongye, Xiangdong and Asiedu, Bernice and Infelise, Patrizia and Barreby, Emelie and Jamialahmadi, Oveis and Mahlapuu, Margit and Mancina, Rosellina M and Romeo, Stefano},
  title = {MTARC1 p.A165 ablation reduces hepatocellular carcinoma aggressiveness in vitro and in vivo},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {829--842},
  doi = {10.3350/cmh.2025.1261}
}
Kostenlos starten →